FDA approves CRM monitoring system

Candace Stuart | | Cardiovascular Business | Heart Rhythm

The FDA approved Smartview technology to remotely monitor patients with implanted cardiac rhythm management (CRM) devices. The system allows patients to transmit data electronically from implanted cardiac devices to their physicians.

The system uses Smartview and Paradym RF devices, according to manufacturer Sorin Group, which initiated its U.S. launch of the Paradym RF VR and DR implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices in May 2012.

The Milan, Italy-based company said it was now beginning its launch of Smartview in the U.S.

Candace Stuart, Contributor

Related Content

Johnson & Johnson gains CE mark approval for catheter capable of radiofrequency, PFA ablation
Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications
History made: Young child treated with new heart device for very first time
ACC offers practical approaches for arrhythmia monitoring after stroke
FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.